BIBF1120 in patients with advanced FGFR3 mutated, FGFR3 overexpressed, or FGFR3 wild type urothelial carcinoma of urinary bladder, urethra, ureter, and renal pelvis and who have failed platinum-based chemotherapy.

Inclusion Criteria:

• KPS 60%
• Histological confirmation of urothelial carcinoma , with metastatic disease
• Measurable disease
• Previously treated with platinum-based chemotherapy administered

Exclusion Criteria:

• Radiographic evidence of cavitary or necrotic tumours
• Active brain metastasis.Leptomeningeal metastasis
• Chemotherapy, radiotherapy, targeted therapy with monoclonal antibodies or small tyrosine kinase inhibitors
• Grade 1 treatment-related toxicity from previous chemotherapy, radiotherapy, or targeted therapy
• Prior treatment with BIBF 1120 or other VEGFR inhibitors
• Significant cardiovascular diseases:
• Pericardial effusion
• Significant bleeding or thrombosis
• Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
• Major injuries within the past 10 days with incomplete wound healing and/or planned surgery during the on-treatment study period